Bioactive Compounds for Effective Management of Drug-Resistant Tuberculosis

Author(s): Monika Targhotra*, Rohan Aggarwal, Meenakshi K. Chauhan

Journal Name: Current Bioactive Compounds

Volume 17 , Issue 3 , 2021

Article ID: e180520182066
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Tuberculosis is a granulomatous irresistible bacterial infection caused by Mycobacterium tuberculosis. The present anti-TB antibiotics are less useful in the treatment of Multi- Drug-Resistant (MDR) strains.

Methods: We focused on distinguishing phyto-bioactive compounds dependent on customary uses and testing their concentrates against MDR strains. This will help abbreviate the present remedial regimens for TB and for treating HIV-TB co-disease.

Results: This article is an endeavor to examine the antimycobacterial and immunomodulatory role of phyto-bioactive compounds as another option and feature them for additional examination for the management of drug-resistant tuberculosis.

Conclusion: This review focused on the tubercle bacilli utilizing bioactive compounds as the therapeutic vehicle against MDR strains and also the synergistic action with available TB medications.

Keywords: Tuberculosis, mycobacterium, isoniazid, MDR, phyto-bioactive, natural, antimycobacterial.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 06 May, 2021
Article ID: e180520182066
Pages: 10
DOI: 10.2174/1573407216999200518090132
Price: $65

Article Metrics

PDF: 65